Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
WeybridgeSurreyKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
24,524
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
stocks
Our top ASX picks in every sector
stocks
Which of the 3 giant AI IPOs should you buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,864.80 | 34.90 | -0.39% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 25,254.49 | 39.54 | -0.16% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 53,395.13 | 344.55 | -0.64% |
| NZX 50 Index | 12,912.10 | 86.23 | 0.67% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,661.80 | 23.20 | -0.27% |
| SSE Composite Index | 3,948.55 | 0.00 | 0.00% |